Clinical Trial Search

Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%

Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001

Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale

Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602

Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants

Primary: Change in Daily Urine Volume From Baseline — 18.3 mL

Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…

Primary: Phosphorus Levels — 5.3; 5.6; 5.4; 6 mg/dL

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Mortality — 0; 0 percentage of mortality

Primary: Patients' Adherence to Study Protocol — 22; 24; 19; 19 Participants

Primary: Change From Baseline in Daily Urine Volume — 481.0 ml

Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001

Primary: Percentage of Participants Maintaining Mean Hemoglobin Concentration Within +/- 1 g/dL of Their Reference Hb and Between 10.5 and 12.5 g/dL During Efficacy Evaluation…

Primary: Percentage of Participants Maintaining Mean Hemoglobin Levels Within the Target Range During the Last 4 Weeks of the Treatment Period (Weeks 8 to 12) — 57.89 Percentage…

Primary: 60 Day Mortality — 11 Participants

Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008

Primary: Patients With an Increase in Hemoglobin >= 1gm/dL. — 35; 23 participants

Primary: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and…

Primary: Percentage of Participants Maintaining Hb Concentration Within +/-1 Gram Per Deciliter (g/dL) of Their Reference Hb and Between 10.5 to 12.5 g/dL Throughout the Efficacy…

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants

Primary: Mean Feasibility of Intervention Measure — 16.4; 16.1; 19.0 score on a scale

Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L

Primary: Change From Baseline in Mean Hb Concentration at Week 20 — 8.820; 1.440 Grams per deciliter (gm/dL) — p=<0.0001

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase — 15; 5 Participants — p=0.006

Primary: Percentage of Participants Who Maintained Their Mean Hemoglobin Concentration Within +/- 1.0 Gram/Deciliter of Their Reference Hemoglobin Concentration and Between 10.0…

Primary: Percentage of Participants Who Maintained Average Hb Value Within Target Range During the EEP — 50.0 percentage of participants

Primary: Percentage of Participants Maintaining Average Hemoglobin Concentration Within +- 1 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter During…